Elsevier

The Lancet

Volume 345, Issue 8961, 27 May 1995, Pages 1321-1325
The Lancet

Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection

https://doi.org/10.1016/S0140-6736(95)92534-1Get rights and content

Abstract

Preliminary studies suggested that mycophenolate mofetil (MMF), which inhibits proliferation of T and B cells, may reduce the frequency of acute rejection after renal transplantation. Our randomised, double-blind, multicentre, placebo-controlled study compared the efficacy and safety of MMF with placebo for prevention of acute rejection episodes after first or second cadaveric renal allograft transplantation. 491 patients were enrolled; 166 were assigned placebo, 165 MMF 2 g, and 160 MMF 3 g. Patients also received cyclosporin and corticosteroids. Significantly fewer (p·0001) patients had biopsy-proven rejection or withdrew early from the trial (for any reason) during the first 6 months after transplantation with MMF 2 g (30.3%) or 3 g (38.8%) than with placebo (56·0%). The corresponding percentages for biopsy-proven rejection were 17.0%, 13.8%, and 46.4%. 28.5% of MMF 2 g and 24.4% of MMF 3 g patients needed full courses of corticosteroids or antilymphocyte agents for treatment of rejection episodes in the first 6 months, compared with 51.8% of placebo recipients. By 6 months, 10.2%, 6.7%, and 8.8% of the patients in the placebo, MMF 2 g, and MMF 3 g groups, respectively, had died or lost the graft. Overall, the frequency of adverse events was similar in all treatment groups, although gastrointestinal problems, leucopenia, and opportunistic infections were more common in the MMF groups and there was a trend for more events in the 3 g than the 2 g group. MMF significantly reduced the rate of biopsy-proven rejection or other treatment failure during the first 6 months after transplantation and was well tolerated. The 3 g dose was somewhat less well tolerated.

References (19)

  • K. Solez et al.

    International standardisation of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology

    Kidney Int

    (1993)
  • Ac Gulanikar et al.

    The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants

    Transplantation

    (1992)
  • H. Koyama et al.

    Rejection episodes

  • A. Lindholm et al.

    The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporin regimens

    Transplantation

    (1993)
  • Ps Almond et al.

    Risk factors for chronic rejection in renal allograft recipients

    Transplantation

    (1993)
  • Rj Tesi et al.

    Predictors of long-term primary cadaveric renal transplant survival

    Clin Transplant

    (1993)
  • A. Lindholm et al.

    A randomised trial of cyclosporin and prednisolone versus cyclosporin, azathioprine, and prednisolone in primary cadaveric renal transplantation

    Transplantation

    (1992)
  • DW. Gjertson

    Survival trends in long-term first cadaver donor kidney transplants

  • Re Morris et al.

    Mycophenolic acid morpholinoethylester (RS-6134) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T and B cell purine synthesis

    Transplant Proc

    (1990)
There are more references available in the full text version of this article.

Cited by (1128)

View all citing articles on Scopus

Correspondence to: Prof R Pichlmayr, Medizinische Hochschule Hannover, Klinik für Abdominal und Transplantationschirurgie, D-30625 Hannover, Germany

1

Participants listed at end of paper

View full text